The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Secondary rectal cancer tumors that develop years after prostate cancer radiation therapy appear to differ in distinct ways from primary rectal cancers.

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

Clinicians should not neglect proteinuria testing in adults younger than age 40 years to identify those at high risk for sudden cardiac arrest.

GAGome score had 90 percent sensitivity, 51 percent specificity for radiological recurrence, with AUC of 0.73 for nonmetastatic clear-cell renal cell carcinoma.

(HealthDay News) — Subclinical cardiac dysfunction is associated with brain imaging markers of neurodegeneration, according to a study published online March 26 in Neurology.

(HealthDay News) — Colorectal cancer (CRC) is tied to an increased risk for cardiovascular mortality, especially in individuals younger than 50 years, according to a study presented at the annual ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

The presence of residual tumor cells in the trigone and urethra after robot-assisted radical cystectomy (RARC) is associated with a higher tumor stage, positive margins, and cancer recurrence compared ...

A trial tested MRI and microultrasonography guided biopsy separately and in combination for the detection of clinically significant prostate cancer.

Maintaining systolic blood pressure consistently below 130 mmHg could help decrease the risk for new-onset diabetes in the ...

The Senate has confirmed Dr Jay Bhattacharya as the new director of the NIH and Dr Marty Makary as the new commissioner of the FDA.